

## Early and locally advanced breast cancer: diagnosis and management – further surgery to the breast (update)

### Advisory Committee Interests Register

Register last updated: 5/1/2024

| Name              | Role with NICE                    | Type of interest | Description of interest  | Interest arose | Interest declared | Interest ceased | Comments  |
|-------------------|-----------------------------------|------------------|--|----------------|-------------------|-----------------|---|
| Adam Firth        | Guideline Committee Chair         | Direct financial | GP Partner, Bracondale Medical Centre, Stockport   | July 2013      | May 2022          | Ongoing         | Declare and participate.<br>Rationale: Salaried employment in NHS. Interest is non-specific.<br>Agreed by:<br>Guideline Lead Oct 2023 |
| Kwok Leung Cheung | Committee member – Breast Surgeon | Direct financial | Professor of Breast Surgery and Medical Education, University of Nottingham (substantive employer) |                | Dec 2022          | Ongoing         | Declare and participate.<br>Rationale: Salaried employment as clinical academic.<br>Agreed by:<br>Guideline Lead Oct 2023             |

|                   |                                   |   |  |      |           |         |   |
|-------------------|-----------------------------------|---|--|------|-----------|---------|---|
| Kwok Leung Cheung | Committee member – Breast Surgeon | Direct, non-financial professional and personal | Honorary Consultant Breast Surgeon, University Hospitals of Derby and Burton NHS Foundation Trust (honorary employer)              |      | Dec 2022  |         | Declare and participate.<br>Rationale: Honorary employment in NHS.<br>Agreed by: Guideline Lead Oct 2023                |
| Kwok Leung Cheung | Committee member – Breast Surgeon | Direct financial                                | Private clinical practice in Breast Surgery at Derby Private Health.<br><br>Private practice accounts for <5% of overall practice. | 2001 | July 2022 | Ongoing | Declare and participate.<br>Rationale: private practice is limited.<br>Agreed by: Guideline Lead Oct 2023               |
| Kwok Leung Cheung | Committee member – Breast Surgeon | Non-financial professional and personal         | External professional Advisor to the Parliamentary and Health Service Ombudsman for Breast surgery and breast cancer.              | 2008 | July 2022 | Ongoing | Declare and participate.<br>Rationale: open declaration is sufficient mitigation.<br>Agreed by: Guideline Lead Oct 2023 |

|                   |                                   |   |   |              |            |         |  |
|-------------------|-----------------------------------|---|---|--------------|------------|---------|--|
| Kwok Leung Cheung | Committee member – Breast Surgeon | Non-financial professional and personal | UK National Representative, International Society of Geriatric Oncology (SIOG)  | 2013         | July 2022  | ongoing | Declare and participate.<br>Rationale: interest is non-specific.<br>Agreed by: Guideline Lead Oct 2023 |
| Kwok Leung Cheung | Committee member – Breast Surgeon | Non-financial professional and personal | Member, SIOG Public Policy Ad-hoc Committee   | October 2021 | July 2022  | Ongoing | Declare and participate.<br>Rationale: interest is non-specific.<br>Agreed by: Guideline Lead Oct 2023 |
| Kwok Leung Cheung | Committee member – Breast Surgeon | Non-financial professional and personal | Member, Surgical Speciality Board in General Surgery (sub-speciality breast surgery), Royal College of Surgeons Edinburgh | July 2022    | July 2022  | Ongoing | Declare and participate.<br>Rationale: interest is non-specific.<br>Agreed by: Guideline Lead Oct 2023 |
| Sadaf Haque       | Committee member –                | Direct financial                        | Salaried General Practitioner, Rosebank Health Primary Care Network, Gloucester   | 2017         | March 2023 | ongoing | Declare and participate.   |

|             |   |                  |  |      |            |         |  |
|-------------|---|------------------|--|------|------------|---------|--|
|             | General Practitioner                    |                  |  |      |            |         | Rationale: Salaried employment in NHS. Interest is non-specific.<br>Agreed by: Guideline Lead Oct 2023   |
| Sadaf Haque | Committee member – General Practitioner | Direct financial | Clinical Lead Cancer, NHS Gloucestershire  | 2013 | March 2023 | ongoing | Declare and participate.<br>Rationale: Salaried employment in NHS.<br>Agreed by: Guideline Lead Oct 2023 |
| Sadaf Haque | Committee member – General Practitioner | Direct financial | Breast Physician, Gloucestershire Hospitals NHS Foundation Trust   | 2022 | March 2023 | Ongoing | Declare and participate.<br>Rationale: Salaried employment in NHS.<br>Agreed by: Guideline Lead Oct 2023 |
| Sadaf Haque | Committee member – General Practitioner | Direct financial | Chair Gloucestershire GP Education Trust - this is a membership charitable organisation, offering aspirational GP education with | 2013 | March 2023 | Ongoing | Declare and participate.<br>Rationale: Interest is non-specific.   |

|          |                               |                  |   |              |          |         |   |
|----------|-------------------------------|------------------|---|--------------|----------|---------|---|
|          |                               |                  | local provider colleagues and as Education Programme Director and Honorary Tutor I take an active role in forming policy/ strategy and planning/ facilitating educational events. I kite-mark all GGPET education sessions for quality of GP education. I attend NHS Gloucestershire's monthly HEE Training Hub meetings. |              |          |         | Agreed by:<br>Guideline Lead Oct 2023   |
| Katy Tan | Committee member - Lay member | Direct financial | Employment – Reckitt (a hygiene, health and nutrition company).   | January 2009 | Aug 2022 | Ongoing | Declare and participate.<br>Rationale: Salaried position. Interest is non-specific to breast cancer.<br><br>Agreed by:<br>Guideline Lead Oct 2023 |
| Katy Tan | Committee member - Lay member | Direct financial | Shareholder – Reckitt (a hygiene, health and nutrition company).  | 2014         | Aug 2022 | Ongoing | Declare and participate.<br>Rationale: interest is non-specific to breast cancer.   |

|                     |  |                  |  |             |               |          |  |
|---------------------|--|------------------|--|-------------|---------------|----------|--|
|                     |  |                  |  |             |               |          | Agreed by:<br>Guideline Lead Oct<br>2023   |
| Katy Tan            | Committee<br>member -<br>Lay<br>member                   | Direct financial | Shareholder – Indivor<br>(pharmaceutical company for<br>addiction and serious mental<br>illness).              | 2014        | Aug<br>2022   | Ongoing  | Declare and<br>participate.<br><br>Rationale: interest<br>is non-specific to<br>breast cancer.<br><br>Agreed by:<br>Guideline Lead Oct<br>2023 |
| Caroline<br>Tweedie | Committee<br>member –<br>Clinical<br>Nurse<br>Specialist | Direct financial | Breast Care Nurse Specialist,<br>Queen Elizabeth Hospital  | Feb<br>2023 | March<br>2023 | Present  | Declare and<br>participate.<br><br>Rationale: Salaried<br>employment in<br>NHS.<br><br>Agreed by:<br>Guideline Lead Oct<br>2023                |
| Caroline<br>Tweedie | Committee<br>member –<br>Clinical<br>Nurse<br>Specialist | Direct financial | Direct payment from the<br>commercial sector to deliver a<br>presentation regarding lifestyle<br>breast cancer | Oct 2022    | Feb<br>2023   | Oct 2022 | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.   |

|                     |  |                  |  |             |             |             |   |
|---------------------|--|------------------|--|-------------|-------------|-------------|---|
|                     |  |                  |  |             |             |             | Agreed by<br>Guideline Lead Oct<br>2023   |
| Caroline<br>Tweedie | Committee<br>member –<br>Clinical<br>Nurse<br>Specialist | Direct financial | Direct Payment from<br>commercial Sector to deliver a<br>presentation regarding lifestyle<br>and Breast Cancer   | Jan 2023    | Feb<br>2023 | Jan 2023    | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.<br><br>Agreed by<br>Guideline Lead Oct<br>2023 |
| Caroline<br>Tweedie | Committee<br>member –<br>Clinical<br>Nurse<br>Specialist | Direct financial | Direct payment from commercial<br>sector chair to present at a<br>regional NHS conference.<br><br>Presentation was on lifestyle<br>and the implications on survival<br>and QOL | Feb<br>2022 | Feb<br>2023 | Feb<br>2023 | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.<br><br>Agreed by<br>Guideline Lead Oct<br>2023 |
| Caroline<br>Tweedie | Committee<br>member –<br>Clinical<br>Nurse<br>Specialist | Direct financial | Direct payment from commercial<br>sector to present at a regional<br>NHS conference.<br><br>Presentation was on lifestyle<br>and the implications on survival<br>and QOL       | Feb<br>2022 | Feb<br>2023 | Feb<br>2023 | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.<br><br>Agreed by<br>Guideline Lead Oct<br>2023 |

|                  |  |   |   |           |           |          |  |
|------------------|--|---|---|-----------|-----------|----------|--|
| Caroline Tweedie | Committee member – Clinical Nurse Specialist | Direct, non-financial professional and personal | A collaborator with Northumbria University Clinical Trails Team for a new trial PURE- EX. Investment received via Breast Cancer Now,<br><br>(EXpanding into communities to imProve lifestyle sUpport foR womEn after breast cancer (PURE-EX). | June 2022 | Feb 2023  | ongoing  | Declare and participate.<br><br>Rationale: Interest is non-specific to this update.<br><br>Agreed by Guideline Lead Oct 2023 |
| Tamsin Sargeant  | Committee Lay Member                         | Nil   |   |           |           |          |  |
| Lisa Whisker     | Committee member – Breast Surgeon            | Direct financial                                | Consultant Oncoplastic Breast Surgeon<br>Nottingham University Hospitals (NUH) NHS Trust  | Sept 2012 | July 2023 | Present  | Declare and participate.<br><br>Rationale: Salaried employment in NHS.<br><br>Agreed by: Guideline Lead Oct 2023             |
| Lisa Whisker     | Committee member – Breast Surgeon            | Direct financial                                | Single fixed fee payment to attend advisory board: Discussion of clinical cases titled:<br>Reflection on clinical practice in patient groups: role of genomic assays. Exact sciences (Oncotype DX )/ Osprey consulting                        | Nov 2022  | July 2023 | Nov 2022 | Declare and participate.<br><br>Rationale: Interest is non-specific to this update.<br><br>Agreed by Guideline Lead Oct 2023 |



|              |                                   |   |   |  |           |         |  |
|--------------|-----------------------------------|---|---|--|-----------|---------|--|
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Clinical Lead for Research in the breast service at NUH NHS trust. We have a portfolio of trials, but none focus on further breast surgery  |  | July 2023 | Ongoing | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Oct 2023 |
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Steering group member for clinical trials:<br><br>ENDONET – RCT evaluating neo-adjuvant hormone therapy.  |  | July 2023 | Ongoing | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Oct 2023 |
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Steering group member for clinical trials<br>ANTHEM – cohort study evaluating oncological safety of breast conserving surgery (including complex oncoplastic procedures) vs mastectomy for larger areas of disease. Primary surgery, not further surgery and now closed to recruitment. |  | July 2023 | Ongoing | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Oct 2023 |

|              |                                   |   |  |            |           |         |  |
|--------------|-----------------------------------|---|--|------------|-----------|---------|--|
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Steering group member for clinical trials<br><br>BEST-BRA – Evaluating pre-pec vs sub-pec reconstruction. Closed to recruitment.   |            | July 2023 | Ongoing | Declare and participate.<br><br>Rationale: Interest is non-specific to this update.<br><br>Agreed by Guideline Lead Oct 2023 |
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Steering group member for clinical trials<br><br>DIAMOND – evaluating drain use in elective breast surgery. Trial design stage.  |            | July 2023 | Ongoing | Declare and participate.<br><br>Rationale: Interest is non-specific to this update.<br><br>Agreed by Guideline Lead Oct 2023 |
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Member of East midlands ECAG (Expert Clinical Advisory Group) for breast surgery, as a regional surgeon treating breast cancer.<br><br>Contribute to regional recommendations and discussions about optimal care for breast cancer patients. | March 2012 | July 2023 | Ongoing | Declare and participate.<br><br>Rationale: Interest is non-specific to this update.<br><br>Agreed by Guideline Lead Oct 2023 |
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Chair of Association of Breast Surgery Guideline Group developing guidelines for management of phyllodes tumours.  | Jan 2022   | July 2023 | Ongoing | Declare and participate.<br><br>Rationale: Interest is non-specific to   |

|              |                                   |   |   |      |           |         |   |
|--------------|-----------------------------------|---|---|------|-----------|---------|---|
|              |                                   |   | A group not covered by this guideline.  |      |           |         | this guideline (NG101).<br>Agreed by<br>Guideline Lead Oct 2023   |
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal | Chair of Guideline Group developing guidelines: Biological and synthetic mesh assisted breast reconstruction procedures: Joint guidelines from the Association of Breast Surgery and the British Association of Plastic, Reconstructive and Aesthetic Surgeons<br><br>Guidelines published 2021<br>EJSO 2021 Nov;47(11):2807-2813.  | 2019 | July 2023 | Ongoing | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by<br>Guideline Lead Oct 2023 |
| Lisa Whisker | Committee member – Breast Surgeon | Indirect financial                      | Department I work in (NHS), on occasions receives financial reimbursement for costs to develop and run feasibility assessment of new interventions (commercial trials). Currently commercial trials evaluating: <ul style="list-style-type: none"> <li>Adiposet fat-banking in serial lipomodelling (fat transfer). Open and patients are being recruited. Eligible patients are post-breast</li> </ul> |      | July 2023 | Ongoing | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by<br>Guideline Lead Oct 2023 |

|              |                                   |  |   |      |           |         |   |
|--------------|-----------------------------------|--|---|------|-----------|---------|---|
|              |                                   |  | <p>cancer surgery.</p> <ul style="list-style-type: none"> <li>• Artia Mesh. Safety evaluation in breast reconstruction. Trial in development</li> <li>• IBREX2. Mesh safety evaluation in breast reconstruction. Trial in development. No estimated start date.</li> </ul> <p>I am not personally involved in trial development/trial management team for these trials.</p> |      |           |         |   |
| Lisa Whisker | Committee member – Breast Surgeon | Non-financial professional and personal and indirect financial | <p>Local (NUH NHS site) PI for the PICO 14 trial (a commercial trial that is developed outside the department / trust – see DOI above this). Trial has completed recruitment and subject follow-up. Awaiting data lock.</p> <p>My department (NHS) receives reimbursement costs to run commercial trials outside of trust</p>   |      | July 2023 | Ongoing | <p>Declare and participate.</p> <p>Rationale: Interest is non-specific to this update.</p> <p>Agreed by Guideline lead October 2023</p> |
| Lisa Whisker | Committee member – Breast Surgeon | Indirect financial   | <p>Reviewer of patient information leaflets (breast surgery) for EIDO Healthcare with my local NHS colleagues. The department I work in will receive a donation for our time.</p>   | 2019 | July 2023 | Ongoing | <p>Declare and participate.</p> <p>Rationale: Interest is non-specific to this update.</p>  |

|                |                                |   |  |            |           |         |   |
|----------------|--------------------------------|---|--|------------|-----------|---------|---|
|                |                                |   | <p>The NHS trust I work in has an established link with EIDO Healthcare for provision of surgical patient information. The work I have contributed (with my colleagues) is to ensure up to date / accurate information is provided for patients undergoing breast surgery.</p> <p>Recommendations from NICE guidance are included in the patient information if appropriate.</p> |            |           |         | Agreed by<br>Guideline lead<br>October 2023   |
| Hannah Markham | Committee member – Pathologist | Direct financial                        | Consultant Histopathologist, University Hospital Southampton   | 2013       | Sept 2023 | Present | <p>Declare and participate.</p> <p>Rationale: Salaried employment in NHS.</p> <p>Agreed by:<br/>Guideline Lead Oct 2023</p>             |
| Hannah Markham | Committee member – Pathologist | Non-financial professional and personal | NCRI Breast Cancer CSG-member as a pathology advisor who gives guidance on pathology requirements in trials. NCRI currently folding and this group may no longer meet.   | April 2019 | Sept 2023 | Ongoing | <p>Declare and participate.</p> <p>Rationale: Interest is non-specific to this update.</p> <p>Agreed by<br/>Guideline Lead Oct 2023</p> |

|                  |                                |                  |   |          |           |          |  |
|------------------|--------------------------------|------------------|---|----------|-----------|----------|--|
| Hannah Markham   | Committee member – Pathologist | Direct financial | Speaker fee from Astra Zeneca. Wessex Cancer Genetics Regional Meeting- BRCA testing in Prostate Cancer, a pathologist's perspective. | Dec 2023 | Dec 2023  | Jan 2024 | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Jan 2024 |
| Elena Provenzano | Committee member – Pathologist | Direct financial | Lead Breast Pathologist, Addenbrooke's Hospital, Cambridge  | Jan 2013 | Sept 2023 | Present  | Declare and participate.<br>Rationale: Salaried employment in NHS.<br>Agreed by: Guideline Lead Oct 2023             |
| Elena Provenzano | Committee member – Pathologist | Direct financial | Advisory Board BRCA1 testing Astra Zeneca   | May 2022 | Sept 2023 | Feb 2023 | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Oct 2023 |
| Elena Provenzano | Committee member – Pathologist | Direct financial | Speakers fees from Astra Zeneca for presentation as part of a meeting on Enhertu  | May 2023 | Sept 2023 | May 2023 | Declare and participate.   |

|                  |                                |   |  |           |           |          |  |
|------------------|--------------------------------|---|--|-----------|-----------|----------|--|
|                  |                                |   | Presentation on HER2 testing in breast cancer and definition of HER2 Low   |           |           |          | Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Oct 2023                             |
| Elena Provenzano | Committee member – Pathologist | Non-financial professional and personal | Co-author of Royal College of Pathologists guidelines for reporting of breast cancer surgical specimens  | July 2020 | Sept 2023 | Ongoing  | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Oct 2023 |
| Elena Provenzano | Committee member – Pathologist | Non-financial professional and personal | Co-author Update to U.K. Recommendations for HER2 Assessment in breast cancer  | Sept 2018 | Sept 2023 | Oct 2022 | Declare and participate.<br>Rationale: Interest is non-specific to this update.<br>Agreed by Guideline Lead Oct 2023 |
| Elena Provenzano | Committee member – Pathologist | Non-financial professional and personal | Member ESMO expert panel on pathologic diagnosis of HER2-Low breast cancer and co-author on Expert consensus statement on the definition, diagnosis and management of HER2-low breast cancer | Aug 2022  | Sept 2023 | Jan 2023 | Declare and participate.<br>Rationale: Interest is non-specific to this update.                                      |

|                           |   |                  |  |             |              |         |  |
|---------------------------|---|------------------|--|-------------|--------------|---------|--|
|                           |   |                  |  |             |              |         | Agreed by<br>Guideline Lead Oct<br>2023  |
| Shiroma De<br>Silva-Minor | Committee<br>member –<br>Clinical<br>oncologist | Direct financial | Consultant in Clinical Oncology<br>Oxford Cancer & Haematology<br>centre<br>Oxford University hospitals NHS<br>Foundation Trust            | Nov<br>2008 | Sept<br>2023 | Present | Declare and<br>participate.<br><br>Rationale: Salaried<br>employment in<br>NHS.<br><br>Agreed by:<br>Guideline Lead Oct<br>2023              |
| Shiroma De<br>Silva-Minor | Committee<br>member –<br>Clinical<br>oncologist | Direct financial | Private practicing privileges with<br>CHG Ridgeway Hospital<br><br>Private practice accounts for<br>approximately 50% of clinical<br>work. | 2009        | Sept<br>2023 | Ongoing | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.<br><br>Agreed by:<br>Guideline Lead Oct<br>2023 |
| Shiroma De<br>Silva-Minor | Committee<br>member –<br>Clinical<br>oncologist | Direct financial | Private practicing privileges<br>Genesiscare.<br><br>Private practice accounts for<br>approximately 50% of clinical<br>work.               | 2013        | Sept<br>2023 | Ongoing | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.   |



|                           |   |                  |  |      |              |         |  |
|---------------------------|---|------------------|--|------|--------------|---------|--|
|                           |   |                  |  |      |              |         | Agreed by:<br>Guideline Lead Oct<br>2023   |
| Shiroma De<br>Silva-Minor | Committee<br>member –<br>Clinical<br>oncologist | Direct financial | Private practicing privileges with<br>BUPA Cromwell<br><br>Private practice accounts for<br>approximately 50% of clinical<br>work.         | 2022 | Sept<br>2023 | Ongoing | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.<br><br>Agreed by:<br>Guideline Lead Oct<br>2023 |
| Shiroma De<br>Silva-Minor | Committee<br>member –<br>Clinical<br>oncologist | Direct financial | Private practicing privileges with<br>CHG Chiltern Hospital<br><br>Private practice accounts for<br>approximately 50% of clinical<br>work. | 2023 | Sept<br>2023 | Ongoing | Declare and<br>participate.<br><br>Rationale: Interest<br>is non-specific to<br>this update.<br><br>Agreed by:<br>Guideline Lead Oct<br>2023 |

## GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.